WebApr 8, 2024 · Cytokinetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes: Voting Procedures; Board Members; ... Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats. Last10K.com Member Feature. Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word … Web2 days ago · Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Phase III Failure Leaves Cytokinetics with One Last Late-Stage …
WebFeb 25, 2024 · Earnings Press Release 10-K Annual Report 10-K YoY Changes Annual Proxy Cytokinetics Inc CIK: 1061983 Ticker: CYTK EXHIBIT 99.1 Cytokinetics Reports … WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. ... 10-K Filing Date. greenlight diecast vehicles
Cytokinetics Reports Second Quarter 2024 Financial Results
WebAug 4, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second … WebMar 31, 2024 · Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function. … WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential … flying-carpet yoshis island